• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Dental Hypotheses >Topical erythropoietin as a novel preventive and therapeutic agent in bisphosphonate-related osteonecrosis of the jaw
【24h】

Topical erythropoietin as a novel preventive and therapeutic agent in bisphosphonate-related osteonecrosis of the jaw

机译：局部促红细胞生成素作为双膦酸酯相关性颌骨坏死的新型预防和治疗剂

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: One of the most common side effects of bisphosphonate intake is osteonecrosis of the jaw (ONJ) which may develop following dentoalveolar interventions. Despite the vast available protocols, there is no clear guideline in the management of this condition. In osteonecrosis, the number and proliferation of bone-forming cells as well as vascularity are disturbed. Erythropoietin (EPO) is a hematopoietic hormone with angiogenic, osteogenic, and antiapoptotic properties. The Hypothesis: It is suggested to utilize poly lactic-co-glycolic acid hydrogel containing 1500-3000 IU/kg EPO following dentoalveolar surgery in samples receiving bisphosphonates as a preventive or therapeutic agent. Evaluation of the Hypothesis: Considering the pathophysiology of ONJ and therapeutic properties of EPO, it is assumed that EPO may be effective in treatment of ONJ. Furthermore, as a preventive measure, utilizing EPO following dentoalveolar surgery may be beneficial in the patients at risk of ONJ.
机译：简介：摄入双膦酸盐最常见的副作用之一是颌骨坏死（ONJ），其可能在牙槽骨干预后发展。尽管有大量可用的协议，但是在这种情况的管理中没有明确的指南。在骨坏死中，破坏了骨形成细胞的数量和增殖以及血管。促红细胞生成素（EPO）是具有血管生成，成骨和抗凋亡特性的造血激素。假设：建议在接受双膦酸盐作为预防剂或治疗剂的样品进行牙槽手术后，使用含有1500-3000 IU / kg EPO的聚乳酸-乙醇酸水凝胶。假设的评估：考虑到ONJ的病理生理和EPO的治疗特性，我们认为EPO可能对ONJ的治疗有效。此外，作为预防措施，在牙槽骨手术后使用EPO可能对有ONJ风险的患者有益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号